Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018173 · ClinicalTrials.gov registry record · Phase 3
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,118
- Enrollment target
NCT01018173 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2,118 participants.
The verdict
NCT01018173, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,118 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly, or weekly sc placebo, in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease. Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.
Interventions
- DRUG placebo
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,118 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018173
The ClinicalTrials.gov registry entry for NCT01018173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01018173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018173 about?
NCT01018173 is a clinical study titled "A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease". This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to recei...
What is the current status of trial NCT01018173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,118 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01018173?
The interventions under investigation include: placebo (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT01018173?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.